Goldman Sachs
SPRB

Goldman Sachs’s Spruce Biosciences SPRB Stock Holding History

Goldman Sachs’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.75M Buy
32,348
+26,842
+488% +$1.5M ﹤0.01% 4787
2026
Q1 		$360K Buy
+5,506
New +$380K ﹤0.01% 5789
2023
Q2 		– Sell
-2,435
Closed -$404K – 6138
2023
Q1 		$404K Buy
+2,435
New +$452K ﹤0.01% 4954
2022
Q4 		– Sell
-261
Closed -$27K – 6310
2022
Q3 		$27K Sell
261
-534
-67% -$74.6K ﹤0.01% 5885
2022
Q2 		$104K Buy
795
+226
+40% +$29K ﹤0.01% 5853
2022
Q1 		$85K Sell
569
-2,508
-82% -$467K ﹤0.01% 6154
2021
Q4 		$1.03M Buy
3,077
+2,904
+1,679% +$864K ﹤0.01% 4812
2021
Q3 		$78K Buy
173
+29
+20% +$18.2K ﹤0.01% 5957
2021
Q2 		$121K Sell
144
-22
-13% -$23.5K ﹤0.01% 5897
2021
Q1 		$207K Buy
+166
New +$255K ﹤0.01% 5626

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return

Goldman Sachs's SPRB Position: Q2 2026 in Review

Goldman Sachs increased its Spruce Biosciences (SPRB) stake by 488% in Q2 2026, buying an estimated $1.5M and bringing the position to 32,348 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #4787.

Goldman Sachs first reported a position in SPRB in Q1 2021 and has held it in 10 quarters since. 57 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • Goldman Sachs held 32,348 shares of Spruce Biosciences worth $1.75M as of Q2 2026.
  • Goldman Sachs bought 26,842 Spruce Biosciences shares in Q2 2026, an estimated $1.5M.
  • Spruce Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4787 holding.
  • Goldman Sachs first reported a position in Spruce Biosciences in Q1 2021 and has held it in 10 quarters since.
  • 57 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.